The Latest Analyst Ratings For Ovid Therapeutics
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for Ovid Therapeutics (NASDAQ: OVID) over the past three months, with a recent average 12-month price target of $4.87, down from $6.44. The company has shown strong revenue growth but faces challenges with profitability and return metrics.
July 26, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Ovid Therapeutics has received mixed analyst ratings, with a recent average price target of $4.87, down from $6.44. The company has shown strong revenue growth but faces challenges with profitability and return metrics.
The mixed analyst ratings and lowered price targets indicate uncertainty about Ovid Therapeutics' short-term performance. While the company has shown strong revenue growth, its profitability and return metrics are concerning, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100